LONG TERM FOLLOW-UP (10 YEARS) OF A PROSPECTIVE TRIAL ASSAY COMPARING LO-TACT-1 ANTIBODY VERSUS ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY IN KIDNEY TRANSPLANTATION.